Literature DB >> 20018583

The use of dry powder inhaler devices by elderly patients suffering from chronic obstructive pulmonary disease.

P Quinet1, C A Young, F Héritier.   

Abstract

UNLABELLED: Twenty-five COPD patients, aged 65years or above, were recruited to test their ability to use dry powder inhaler Handihaler (Boeringher-Ingelheim) and Aerolizer (Novartis). The results of a score created to evaluate the inhalation technique were compared with age, MMSE, Barthel Index, FEV(1), maximum inspiratory and expiratory pressures, and peak inspiratory flow (PIF).
RESULTS: Dry powder inhalers were correctly used by 60% of the patients (15 out of 25). Among the capable ones, 13 out of 15 were aged less than 80 years (p< or =0.02), 13 out of 15 had a maximum inspiratory pressure greater or equal to 53cm H(2)O (p< or =0.001) and a PIF greater or equal to 120l/min (p< or =0.05). All skilled patients had a minimum MMSE of 25 (p< or =0.001).
CONCLUSION: In a geriatric population, age, the decrease of maximum inspiratory pressure and PIF as well as cognitive functions, limit the use of dry powder inhalers. 2009 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20018583     DOI: 10.1016/j.rehab.2009.11.001

Source DB:  PubMed          Journal:  Ann Phys Rehabil Med        ISSN: 1877-0657


  14 in total

Review 1.  Overcoming gaps in the management of chronic obstructive pulmonary disease in older patients: new insights.

Authors:  Jacob Gelberg; R Andrew McIvor
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

Review 2.  Optimizing Drug Therapies in Patients with COPD in the US Nursing Home Setting.

Authors:  Roy A Pleasants; Peter A Radlowski; H Edward Davidson
Journal:  Drugs Aging       Date:  2019-08       Impact factor: 3.923

3.  Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus.

Authors:  Robert A Wise; Russell A Acevedo; Antonio R Anzueto; Nicola A Hanania; Fernando J Martinez; Jill A Ohar; Donald P Tashkin
Journal:  Chronic Obstr Pulm Dis       Date:  2016-11-15

Review 4.  Epidemiology and management of common pulmonary diseases in older persons.

Authors:  Kathleen M Akgün; Kristina Crothers; Margaret Pisani
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-02-15       Impact factor: 6.053

Review 5.  Managing older patients with coexistent asthma and chronic obstructive pulmonary disease: diagnostic and therapeutic challenges.

Authors:  Vanessa M McDonald; Isabel Higgins; Peter G Gibson
Journal:  Drugs Aging       Date:  2013-01       Impact factor: 3.923

Review 6.  A review of nebulized drug delivery in COPD.

Authors:  Donald P Tashkin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-10-18

Review 7.  Recognition, diagnosis, and treatment of cognitive and psychiatric disorders in patients with COPD.

Authors:  Daniel R Ouellette; Kim L Lavoie
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-02-16

8.  A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease.

Authors:  Krishna K Pudi; Chris N Barnes; Edmund J Moran; Brett Haumann; Edward Kerwin
Journal:  Respir Res       Date:  2017-11-02

9.  Pharmacists' training to improve inhaler technique of patients with COPD in Vietnam.

Authors:  Tu-Son Nguyen; Thi Lien Huong Nguyen; Thi Thuy Van Pham; Susan Hua; Quy Chau Ngo; Shu Chuen Li
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-06-11

10.  Efficacy of Umeclidinium/Vilanterol in Elderly Patients with COPD: A Pooled Analysis of Randomized Controlled Trials.

Authors:  Riju Ray; Lee Tombs; Michael J Asmus; Isabelle Boucot; David A Lipson; Chris Compton; Ian Naya
Journal:  Drugs Aging       Date:  2018-07       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.